GlassScriptPhysician profile
Olivia Camille Martinez
NPI 1174297709
$6,115.70
in general payments reported to CMS, 2019-2025
28 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $1,316 · 2024: $2,639 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,899 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,898.82 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,043.88 | 2023-2025 | |
| Glaxosmithkline, LLC. | $877.26 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $709.18 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $498.71 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $400.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $375.93 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $340.20 | 2023-2025 | |
| Astellas Pharma US INC | $298.80 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.33 | 2023-2024 | Jardiance, Ofev |
| Abbott Laboratories | $163.71 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $153.54 | 2024 | Keytruda, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $128.93 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $128.00 | 2024 | |
| Genzyme Corporation | $123.93 | 2023 | |
| Janssen Pharmaceuticals, INC | $122.46 | 2024 | Invega Sustenna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.84 | 2023-2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $94.50 | 2023 | Quviviq |
| Amgen INC. | $73.61 | 2023-2025 | Evenity, Repatha, Otezla |
| Alnylam Pharmaceuticals INC. | $61.58 | 2023-2024 | Givlaari |
| Alk-Abello, INC | $56.02 | 2025 | |
| Boston Scientific Corporation | $36.84 | 2024 | Apollo Esg System |
| Sanofi-Aventis U.S. LLC | $31.28 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.85 | 2023-2024 | |
| Lundbeck LLC | $20.60 | 2025 | Rexulti |
| Averitas Pharma INC. | $17.48 | 2024 | Qutenza |
| Axsome Therapeutics, INC. | $14.72 | 2023 | Auvelity |
| Xeris Pharmaceuticals, INC. | $14.45 | 2024 | Gvoke Hypopen |
| Organon LLC | $4.53 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.